Regeneus Ltd. (AU:CMB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cambium Bio Limited, a Sydney-based regenerative medicine firm, has fortified its leadership by appointing ocular immunology expert Dr. Louis Tong to its Scientific Advisory Board and pharmaceutical veteran Dr. ChiTai Chang to its Board of Directors. These strategic appointments are set to bolster the company’s scientific expertise and strategic business development as it advances its lead product, Elate Ocular®, targeting dry eye disease. The company is focused on ophthalmic and tissue repair therapeutics, with a commitment to ushering its clinical pipeline to market.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.